Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Colorectal Neoplasms

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 81 articles: HTML format

Single Articles

October 2021
1. ZHU Y, Huang Y, Hu Y, Fang Y, et al
   Long-term Risk of Colorectal Cancer after Removal of Adenomas during Screening Colonoscopies in a Large Community-based Population in China.
   Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33835.
   PubMed     Abstract available
   
   
   September 2021
2. HUGEN N, Kanne H, Simmer F, van de Water C, et al
   Umbilical metastases: Real-world data shows abysmal outcome.
   Int J Cancer. 2021;149:1266-1273.
   PubMed     Abstract available
   
   
   
3. MI N, Huang J, Huang C, Lin Y, et al
   High serum uric acid may associate with the increased risk of colorectal cancer in females: A prospective cohort study.
   Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33807.
   PubMed     Abstract available
   
   
   
4. BOYLE JM, Kuryba A, Cowling TE, van der Meulen J, et al
   Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: a national population-based study.
   Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33806.
   PubMed     Abstract available
   
   
   
5. LYNCH KT, Squeo GC, Kane WJ, Meneveau MO, et al
   A Pilot Trial of Vaccination with CEA and Her2 Peptides in Advanced Colorectal Cancer.
   Int J Cancer. 2021 Sep 3. doi: 10.1002/ijc.33793.
   PubMed     Abstract available
   
   
   
6. BUCKSCH K, Zachariae S, Ahadova A, Aretz S, et al
   Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X.
   Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.
   PubMed     Abstract available
   
   
   August 2021
7. LANSDORP-VOGELAAR I, Meester R, de Jonge L, Buron A, et al
   Risk-stratified strategies in population screening for colorectal cancer.
   Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33784.
   PubMed     Abstract available
   
   
   
8. KOCH T, Therming Jorgensen J, Christensen J, Duun-Henriksen AK, et al
   Bilateral Oophorectomy and Rate of Colorectal Cancer: A Prospective Cohort Study.
   Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33776.
   PubMed     Abstract available
   
   
   
9. HE Y, Zhang X, Timofeeva M, Farrington SM, et al
   Bi-directional Mendelian randomisation analysis of the relationship between circulating vitamin D concentration and colorectal cancer risk.
   Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33779.
   PubMed     Abstract available
   
   
   
10. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available
    
    
    
11. MOCHIZUKI Y, Funayama R, Shirota M, Kikukawa Y, et al
    Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.
    Int J Cancer. 2021 Aug 4. doi: 10.1002/ijc.33758.
    PubMed     Abstract available
    
    
    July 2021
12. STAHLER A, Heinemann V, Holch JW, von Einem JC, et al
    Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33747.
    PubMed     Abstract available
    
    
    
13. WATTS K, Wills C, Madi A, Palles C, et al
    Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    Int J Cancer. 2021 Jul 16. doi: 10.1002/ijc.33739.
    PubMed     Abstract available
    
    
    
14. KOSTOS L, Hong W, Lee B, Tran B, et al
    Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
    Int J Cancer. 2021;149:409-419.
    PubMed     Abstract available
    
    
    
15. NADEEM A, Aung KM, Ray T, Alam A, et al
    Suppression of beta-catenin signaling in colon carcinoma cells by a bacterial protein.
    Int J Cancer. 2021;149:442-459.
    PubMed     Abstract available
    
    
    
16. CHENG CY, Datzmann T, Hernandez D, Schmitt J, et al
    Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33728.
    PubMed     Abstract available
    
    
    
17. PAPADIMITRIOU N, Gunter MJ, Murphy N, Gicquiau A, et al
    Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33725.
    PubMed     Abstract available
    
    
    June 2021
18. GULLICKSON C, Goodman M, Joko-Fru YW, Gnangnon FHR, et al
    Colorectal cancer survival in sub-Saharan Africa by age, stage at diagnosis, and Human Development Index: A population-based registry study.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33715.
    PubMed     Abstract available
    
    
    
19. CHAUDHARY N, Choudhary BS, Shah SG, Khapare N, et al
    Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33711.
    PubMed     Abstract available
    
    
    
20. MARCION G, Hermetet F, Neiers F, Uyanik B, et al
    Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer.
    Int J Cancer. 2021;148:3019-3031.
    PubMed     Abstract available
    
    
    
21. 
    Retraction: DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-kB pathway in colorectal cancer. Weiying Liu, Shixing Wang, Qi Sun, Zhen Yang, Min Liu and Hua Tang. Int J Cancer. 2018 May 15;142(10):2068-2079.
    Int J Cancer. 2021 Jun 1. doi: 10.1002/ijc.33671.
    PubMed    
    
    
    May 2021
22. ZORZI M, Battagello J, Fiore A, Memo L, et al
    Colorectal cancer incidence and mortality after negative fecal immunochemical tests by age 70: a prospective observational study.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33682.
    PubMed     Abstract available
    
    
    
23. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available
    
    
    
24. SHAH R, Chan KKW
    The Impact of Socioeconomic Status on Stage at Presentation, Receipt of Diagnostic Imaging, Receipt of Treatment, and Overall Survival in Colorectal Cancer Patients.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33622.
    PubMed     Abstract available
    
    
    
25. FANG Z, Hang D, Wang K, Joshi A, et al
    Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33621.
    PubMed     Abstract available
    
    
    
26. VAUGHAN-SHAW PG, Timofeeva M, Ooi LY, Svinti V, et al
    Differential genetic influences over colorectal cancer risk and gene expression in large bowel mucosa.
    Int J Cancer. 2021 May 2. doi: 10.1002/ijc.33616.
    PubMed     Abstract available
    
    
    April 2021
27. AGLAGO EK, Murphy N, Huybrechts I, Nicolas G, et al
    Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the EPIC cohort.
    Int J Cancer. 2021 Apr 28. doi: 10.1002/ijc.33615.
    PubMed     Abstract available
    
    
    
28. LEE SH, Song IH, Jang HJ
    Feasibility of deep learning-based fully automated classification of microsatellite instability in tissue slides of colorectal cancer.
    Int J Cancer. 2021 Apr 13. doi: 10.1002/ijc.33599.
    PubMed     Abstract available
    
    
    
29. WANG Y, Zhang Y, Qian Y, Xie YH, et al
    Alterations in the Oral and Gut Microbiome of Colorectal Cancer Patients and Association with Host Clinical Factors.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33596.
    PubMed     Abstract available
    
    
    
30. DORIA-ROSE VP, Lansdorp-Vogelaar I, McCarthy S, Puricelli-Perin DM, et al
    Measures of longitudinal adherence to fecal-based colorectal cancer screening: literature review and recommended approaches.
    Int J Cancer. 2021 Apr 3. doi: 10.1002/ijc.33589.
    PubMed     Abstract available
    
    
    
31. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available
    
    
    
32. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    PubMed     Abstract available
    
    
    
33. FLATIN BTB, Vedeld HM, Pinto R, Langerud J, et al
    Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.
    Int J Cancer. 2021;148:1652-1657.
    PubMed     Abstract available
    
    
    
34. APARICIO T, Svrcek M, Henriques J, Afchain P, et al
    Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
    Int J Cancer. 2021;148:1731-1742.
    PubMed     Abstract available
    
    
    
35. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    PubMed     Abstract available
    
    
    March 2021
36. ZHOU J, Ge X, Fan X, Wang J, et al
    Associations of vitamin D status with colorectal cancer risk and survival.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33580.
    PubMed     Abstract available
    
    
    
37. INDUKURI R, Jafferali MH, Song D, Damdimopoulos A, et al
    Genome-Wide Estrogen Receptor beta Chromatin Binding in Human Colon Cancer Cells Reveals its Tumor Suppressor Activity.
    Int J Cancer. 2021 Mar 22. doi: 10.1002/ijc.33573.
    PubMed     Abstract available
    
    
    
38. HELGADOTTIR HT, Thutkawkorapin J, Rohlin A, Nordling M, et al
    Identification of known and novel familial cancer genes in Swedish colorectal cancer families.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33567.
    PubMed     Abstract available
    
    
    
39. WEBSTER-CLARK M, Keil AP, Sanoff HK, Sturmer T, et al
    Introducing Longitudinal Cumulative Dose to Describe Chemotherapy Patterns Over Time: Case Study of a Colon Cancer Trial.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33565.
    PubMed     Abstract available
    
    
    
40. QU X, Zhao L, Wang M, Zhang R, et al
    Novel functional variants in the Notch pathway and survival of Chinese colorectal cancer.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33561.
    PubMed     Abstract available
    
    
    
41. VISCONTI P, Parodi F, Parodi B, Casarino L, et al
    Short tandem repeat profiling for the authentication of cancer stem-like cells.
    Int J Cancer. 2021;148:1489-1498.
    PubMed     Abstract available
    
    
    
42. SHEN X, Shen X
    A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
    Int J Cancer. 2021;148:1323-1330.
    PubMed     Abstract available
    
    
    February 2021
43. KIM H, Wang K, Song M, Giovannucci EL, et al
    A comparison of methods in estimating population attributable risk for colorectal cancer in the United States.
    Int J Cancer. 2021 Feb 2. doi: 10.1002/ijc.33489.
    PubMed     Abstract available
    
    
    
44. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    January 2021
45. MAKI-NEVALA S, Ukwattage S, Olkinuora A, Almusa H, et al
    Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33492.
    PubMed     Abstract available
    
    
    
46. JONGENEEL G, Greuter MJ, van Erning FN, Twisk JW, et al
    Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: a prospective cohort study.
    Int J Cancer. 2021 Jan 18. doi: 10.1002/ijc.33472.
    PubMed     Abstract available
    
    
    
47. DOMINGUEZ-VALENTIN M, Sampson JR, Moller P, Seppala TT, et al
    Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum.
    Int J Cancer. 2021;148:512-513.
    PubMed    
    
    
    
48. HE Y, Timofeeva M, Zhang X, Xu W, et al
    Colorectal cancer risk variants rs10161980 and rs7495132 are associated with cancer survival outcome by a recessive mode of inheritance.
    Int J Cancer. 2021 Jan 7. doi: 10.1002/ijc.33465.
    PubMed     Abstract available
    
    
    
49. WANG L, Hang D, He X, Lo CH, et al
    A prospective study of erythrocyte polyunsaturated fatty acids and risk of colorectal serrated polyps and conventional adenomas.
    Int J Cancer. 2021;148:57-66.
    PubMed     Abstract available
    
    
    December 2020
50. LONG L, Yang W, Liu L, Tobias DK, et al
    Dietary intake of branched-chain amino acids and survival after colorectal cancer diagnosis.
    Int J Cancer. 2020 Dec 19. doi: 10.1002/ijc.33449.
    PubMed     Abstract available
    
    
    
51. JENSEN BV, Schou JV, Yilmaz M, Johannesen HH, et al
    Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
    Int J Cancer. 2020 Dec 17. doi: 10.1002/ijc.33448.
    PubMed     Abstract available
    
    
    
52. HEISSER T, Hoffmeister M, Brenner H
    Effects of Screening for Colorectal Cancer: Development, Documentation and Validation of a Multistate Markov Model.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33437.
    PubMed     Abstract available
    
    
    
53. ORNTOFT MW, Jensen SO, Ogaard N, Henriksen TV, et al
    Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33434.
    PubMed     Abstract available
    
    
    
54. INNOMINATO PF, Karaboue A, Focan C, Chollet P, et al
    Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial.
    Int J Cancer. 2020 Dec 3. doi: 10.1002/ijc.33422.
    PubMed     Abstract available
    
    
    November 2020
55. BLAKER H, Haupt S, Morak M, Holinski-Feder E, et al
    Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.
    Int J Cancer. 2020;147:2801-2810.
    PubMed     Abstract available
    
    
    
56. ZHAN T, Faehling V, Rauscher B, Betge J, et al
    Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
    Int J Cancer. 2020 Nov 13. doi: 10.1002/ijc.33393.
    PubMed    
    
    
    October 2020
57. REINHOLDT K, Thomsen LT, Munk C, Dehlendorff C, et al
    Incidence of HPV-related anogenital precancer and cancer in women with diabetes - a nationwide registry-based cohort study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33365.
    PubMed     Abstract available
    
    
    
58. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available
    
    
    
59. HE MM, Fang Z, Hang D, Wang F, et al
    Circulating Liver Function Markers and Colorectal Cancer Risk: A Prospective Cohort Study in the UK Biobank.
    Int J Cancer. 2020 Oct 22. doi: 10.1002/ijc.33351.
    PubMed     Abstract available
    
    
    
60. LI L, Duan Q, Zeng Z, Zhao J, et al
    UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/beta-catenin signaling.
    Int J Cancer. 2020;147:2239-2252.
    PubMed     Abstract available
    
    
    
61. LANG M, Baumgartner M, Rozalska A, Frick A, et al
    Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of Lynch syndrome.
    Int J Cancer. 2020;147:2316-2326.
    PubMed     Abstract available
    
    
    
62. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available
    
    
    
63. GERMANOVA D, Keirsse J, Kohler A, Hastir JF, et al
    Myeloid TNF and HO-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33334.
    PubMed     Abstract available
    
    
    
64. PILLERON S, Charvat H, Araghi M, Arnold M, et al
    Age disparities in stage-specific colon cancer survival across seven countries: an ICBP SURVMARK-2 population-based study.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33326.
    PubMed     Abstract available
    
    
    
65. JARY M, Hasanova R, Vienot A, Asgarov K, et al
    Molecular description of ANGPT2 associated colorectal carcinoma.
    Int J Cancer. 2020;147:2007-2018.
    PubMed     Abstract available
    
    
    September 2020
66. TIE J, Cohen JD, Lo SN, Wang Y, et al
    Prognostic Significance of Post-Surgery Circulating Tumor DNA in Non-Metastatic Colorectal Cancer: Individual Patient Pooled Analysis of Three Cohort Studies.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33312.
    PubMed     Abstract available
    
    
    
67. UNSELD M, Belic J, Pierer K, Zhou Q, et al
    A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy (RELAIS) translational biomarker phase II pilot study.
    Int J Cancer. 2020 Sep 19. doi: 10.1002/ijc.33303.
    PubMed     Abstract available
    
    
    
68. LADIGAN-BADURA S, Vangala DB, Engel C, Bucksch K, et al
    Value of upper GI endoscopy for gastric cancer surveillance in patients with Lynch syndrome.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33294.
    PubMed     Abstract available
    
    
    
69. JANAKIRAMAN H, Zhu Y, Becker SA, Wang C, et al
    Modeling rectal cancer to advance neoadjuvant precision therapy.
    Int J Cancer. 2020;147:1405-1418.
    PubMed     Abstract available
    
    
    August 2020
70. ACHILLI P, Crippa J, Grass F, Larson DW, et al
    Reply to: Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33256.
    PubMed    
    
    
    
71. DIZDAR O
    Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33258.
    PubMed    
    
    
    
72. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available
    
    
    
73. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available
    
    
    
74. TAO W, Artama M, von Euler-Chelpin M, Hull M, et al
    Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study.
    Int J Cancer. 2020;147:728-735.
    PubMed     Abstract available
    
    
    
75. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available
    
    
    July 2020
76. FELGNER S, Sporing I, Pawar V, Kocijancic D, et al
    The immunogenic potential of bacterial flagella for Salmonella-mediated tumor therapy.
    Int J Cancer. 2020;147:448-460.
    PubMed     Abstract available
    
    
    
77. CLIFFORD GM, Georges D, Shiels MS, Engels EA, et al
    A meta-analysis of anal cancer incidence by risk group: towards a unified anal cancer risk scale.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33185.
    PubMed     Abstract available
    
    
    
78. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available
    
    
    May 2020
79. HWANG JH, Yoon J, Cho YH, Cha PH, et al
    A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/beta-catenin signaling.
    Int J Cancer. 2020;146:2877-2890.
    PubMed     Abstract available
    
    
    November 2019
80. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available
    
    
    
81. COMBES JD, Clifford GM, Gunthard HF, Hauser C, et al
    Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: